Current Opinion in Pulmonary Medicine Log in or Register Subscribe to journalSubscribe Get
new issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

Progressive pulmonary fibrosis (PPF), defined as the worsening of various interstitial lung
diseases (ILDs), currently lacks useful biomarkers. To identify novel biomarkers for early …

Rationale: Distinguishing connective tissue disease–associated interstitial lung disease
(CTD-ILD) from idiopathic pulmonary fibrosis (IPF) can be clinically challenging. Objectives …

Idiopathic pulmonary fibrosis (IPF) represents one of the most complex and challenging
human diseases of our time, and the historical evolution of our knowledge about this …

Background We used data from the INMARK trial to investigate associations between
circulating biomarkers of extracellular matrix (ECM) turnover, inflammation and epithelial …

Pulmonary fibrosis is characterized by progressive lung scarring, leading to a decline in lung
function and an increase in morbidity and mortality. This study leverages single-cell …

Rationale: Idiopathic pulmonary fibrosis (IPF) causes irreversible fibrosis of the lung
parenchyma. Although antifibrotic therapy can slow IPF progression, treatment response is …

Matrix stiffening by lysyl oxidase-like 2 (LOXL2)-mediated collagen cross-linking is proposed
as a core feedforward mechanism that promotes fibrogenesis. Failure in clinical trials of …

Rationale: Accelerated biological aging has been implicated in the development of
interstitial lung disease (ILD) and other diseases of aging but remains poorly understood …

Idiopathic pulmonary fibrosis (IPF) is a severe interstitial lung disease characterized by a
grim prognosis, in which various forms of cell death are significant contributors to its …